3 documents found, page 1 of 1
zAvatar-test—a functional precision model to personalize ovarian cancer treatme...
Estrada, Marta F.; Amorim, Filipa; Silva, Filipa Ferreira da; Almeida, Cátia Rebelo de; Fontes, Márcia; Coelho, Ricardo; Ferreira, SóniaIn ovarian cancer, 80% of patients relapse after first-line therapy. In recurrent cases, oncologists lack reliable tests to guide chemotherapy choices, creating an unmet clinical need. Here, we develop the ovarian cancer zebrafish Avatar-test, a functional in vivo model using patient tumor cells implanted in zebrafish embryos to predict treatment responses. We present the largest observational study (32 patient...
Zebrafish Avatar-test forecasts clinical response to chemotherapy in patients w...
Costa, Bruna; Estrada, Marta F.; Gomes, António; Fernandez, Laura M.; Azevedo, José M.; Póvoa, Vanda; Fontes, Márcia; Alves, António; Galzerano, AntónioCancer patients often undergo rounds of trial-and-error to find the most effective treatment because there is no test in the clinical practice for predicting therapy response. Here, we conduct a clinical study to validate the zebrafish patient-derived xenograft model (zAvatar) as a fast predictive platform for personalized treatment in colorectal cancer. zAvatars are generated with patient tumor cells, treated ...
Relapsed Ovarian Cancer patients with ascites and/or pleural effusion still ben...
Rebordão-Pires, Mariana; Estrada, Marta F.; Gomes, António; Silva, Filipa; Baptista, Carlota; Ramos, Maria João; Fortuna, Ana; Simões, Pedro) Background: Relapsed HGSOC with ascites and/or pleural effusion is a poor-prognostic population and poorly represented in clinical studies. We questioned if these patients are worth treating. In other words, if these patients received the most effective treatment, would it change the course of this disease? To our knowledge this is the first real-life study to evaluate this question in this low-survival popul...